Showing 241-250 of 326 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| SOLUBLE LYMPHOCYTE ACTIVATION GENE-3 (s-LAG-3): A POTENTIAL SURROGATE MARKER FOR TYPE-1 DIABETES PROGRESSION AND IMMUNOTHERAPY SUCCESS | Trustees of Indiana University | Jon Piganelli | Cures | 01-July-2025 to 30-June-2026 | $153,000.00 |
| CGM-Derived Glucose Dynamic Index as Diagnostic Marker for Progression to Type 1 Diabetes | Trustees of Indiana University | Viral Shah | Cures | 01-November-2024 to 31-October-2027 | $900,000.00 |
| Safety and Efficacy of Adjunct Therapies in Adults with Type 1 diabetes: multicenter, registry-based study | Trustees of Indiana University | Viral Shah | Improving Lives | 01-September-2025 to 31-August-2028 | $1,603,777.39 |
| Pancreatic Lymph Node T cell Composition and Function in Human Type 1 Diabetes | Trustees of the University of Pennsylvania | Gregory Golden | Cures | 01-April-2023 to 31-March-2026 | $214,356.00 |
| Evaluating gene-modified hypo-immune PSCs for immune evasion in NHPs | Trustees of the University of Pennsylvania | Ji Lei | Cures | 01-June-2025 to 31-May-2027 | $749,999.08 |
| An AI-driven bioelectronics system to accelerate SC-islet maturation | Trustees of the University of Pennsylvania | Juan Alvarez | Cures | 01-April-2025 to 31-March-2026 | $200,000.00 |
| Mapping islet-reactive T cell responses by islet cell co-culture | Trustees of the University of Pennsylvania | Michael Betts | Cures | 01-July-2022 to 30-June-2025 | $820,548.13 |
| Targeted mRNA LNP strategies to modulate lymphocyte migration and Treg function for T1D immunotherapy | Trustees of the University of Pennsylvania | Michael Betts | Cures | 01-September-2024 to 31-August-2027 | $900,000.00 |
| Targeting self-RNA sensing as a trigger of inflammation in type 1 diabetes | Trustees of the University of Pennsylvania | Qin Li | Cures | 01-April-2025 to 31-March-2026 | $199,919.54 |
| Acetazolamide and Tubuloglomerular Feedback in Persons with Type 1 Diabetes: A Clinical Trial | University of California, San Diego | Charles Ginsberg | Improving Lives | 01-November-2022 to 31-October-2026 | $1,356,726.45 |